LVTX: LAVA Therapeutics N.V. Stock

by  •  • Comments Off on LVTX: LAVA Therapeutics N.V. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 34.20
Enterprise Value ($M) -0.59
Book Value ($M) 25.78
Book Value / Share 0.98
Price / Book 1.33
NCAV ($M) 24.41
NCAV / Share 0.93
Price / NCAV 1.40

Profitability (mra)
Return on Invested Capital (ROIC) -0.90
Return on Assets (ROA) -0.28
Return on Equity (ROE) -0.55

Liquidity (mrq)
Quick Ratio 6.73
Current Ratio 6.73

Balance Sheet (mrq) ($M)
Current Assets 69.78
Assets 71.16
Liabilities 45.37
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 11.98
Operating Income -29.69
Net Income -25.11

Cash Flow Statement (mra) ($M)
Cash From Operations -19.54
Cash from Investing 12.47
Cash from Financing -0.57

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-03 13G BML Investment Partners, L.P. 7.40

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2025-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-05 1,800 8,505 21.16
2025-06-04 1,638 21,361 7.67
2025-06-03 7,324 23,824 30.74
2025-06-02 1,940 52,928 3.67

(click for more detail)

Similar Companies
KRYS – Krystal Biotech, Inc. KURA – Kura Oncology, Inc.
KYTX – Kyverna Therapeutics, Inc. LXRX – Lexicon Pharmaceuticals, Inc.
LYEL – Lyell Immunopharma, Inc.


Financial data and stock pages provided by
Fintel.io